Step 5 semaglutide: what actually happens at the 1.7 mg dose

The biggest misconception about step 5: that it is just a formality before the 'real' dose

A common assumption is that 1.7 mg is merely a waiting room for 2.4 mg, something to rush through. The evidence does not support that framing. The full Wegovy titration programme is designed so that each dose level does genuine work: your system adapts, tolerability improves, and weight loss typically continues throughout the schedule, not only once you reach maintenance. In the STEP 1 clinical trial, published in the New England Journal of Medicine, participants lost weight progressively across the titration period, not in a single surge at 2.4 mg. The 1.7 mg phase contributes to that trajectory. Treating it as a box to tick means you are also less likely to report side effects accurately, or to flag that you are tolerating it well enough to proceed. Your prescriber uses that information. It matters.

There is a separate practical reason not to race ahead: dose increases that are too abrupt carry a meaningfully higher risk of nausea, vomiting and, in rare cases, more serious gastrointestinal problems. The month at 1.7 mg is a preparation, not a delay.

What the 1.7 mg dose involves week to week

The injection schedule does not change at step 5. One pre-filled pen, once a week, into the abdomen, thigh or upper arm, rotating the site each time. What changes is the amount of semaglutide delivered. At 1.7 mg, GLP-1 receptor activity is closer to the saturation seen at the maintenance dose, which is why appetite suppression tends to feel more noticeable for many people at this stage rather than earlier in the schedule.

Timing is worth a brief thought. Some patients find it easiest to pick a fixed day each week, not necessarily a Monday, but a day that works around their routine. If a bank holiday or a pre-booked trip shifts things, the NHS semaglutide guidance gives specific advice on flexibility windows; check the patient information leaflet or speak to your prescriber rather than guessing.

Storage remains the same as at earlier steps: refrigerated between 2°C and 8°C. The exact room-temperature window is stated in your product leaflet, refer there for the precise figure rather than relying on general advice online, which varies and is not always accurate for your specific pen format.

Side effects that appear or change at this dose level

Step 5 does not introduce an entirely new side-effect profile. Nausea, loose stools, indigestion and occasional fatigue remain the most common complaints, just as they are at the earlier steps. What some people notice is a brief resurgence of nausea after moving from 1.0 mg to 1.7 mg, the same pattern that many experienced when moving from 0.5 mg to 1.0 mg. It typically eases within a week or two as the body adjusts.

Less common but worth knowing: if you experience severe, persistent abdominal pain that spreads towards your back, seek medical help promptly. The MHRA highlighted acute pancreatitis as a known, if infrequent, risk associated with GLP-1 medicines in a safety communication in early 2026. It is rare, but the symptom pattern is specific enough that it should never be self-managed or waited out. You can also report any suspected side effects through the Yellow Card scheme, the MHRA uses that data to monitor medicines in real-world use.

Dose adjustments, including pausing at 1.7 mg for longer than a month if tolerability is a concern, are entirely within normal clinical practice. A prescriber may recommend staying at this level rather than advancing on the standard schedule, that is a clinically sound decision, not a setback.

From 1.7 mg to 2.4 mg: what to expect at the next step

After a minimum of four weeks at 1.7 mg, most people move to the 2.4 mg maintenance dose, the subject of the next step in the schedule. This is the dose at which the STEP 1 trial produced an average body-weight reduction of around 15% over 68 weeks. That figure applies across the whole treatment period and titration phase, not just the time spent at 2.4 mg, so it contextualises what the full schedule (including the time at 1.7 mg) actually achieves.

If you are considering Wegovy but are not yet on treatment, the broader picture of how semaglutide works, including eligibility and the licensed schedule, is a useful starting point. For a factual look at the costs involved in private treatment, our Wegovy price comparison page sets out what a full private prescription typically includes. And if you are at the stage of weighing up whether this is right for you, speaking to a prescriber is the most direct route to an accurate answer. Check your eligibility through our free consultation, where a GPhC-registered prescriber reads your details the same day.